Genmab A/S (GMAB)
NASDAQ: GMAB · Real-Time Price · USD
21.02
+0.44 (2.14%)
Dec 27, 2024, 4:00 PM EST - Market closed
Genmab Revenue
Genmab had revenue of 5.54B DKK in the quarter ending September 30, 2024, with 17.57% growth. This brings the company's revenue in the last twelve months to 19.84B, up 17.75% year-over-year. In the year 2023, Genmab had annual revenue of 16.47B with 13.57% growth.
Revenue (ttm)
19.84B DKK
Revenue Growth
+17.75%
P/S Ratio
n/a
Revenue / Employee
9,003,630 DKK
Employees
2,204
Market Cap
13.39B USD
Revenue Chart
* This company reports financials in DKK.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 16.47B | 1.97B | 13.57% |
| Dec 31, 2022 | 14.51B | 6.09B | 72.33% |
| Dec 31, 2021 | 8.42B | -1.69B | -16.75% |
| Dec 31, 2020 | 10.11B | 4.75B | 88.43% |
| Dec 31, 2019 | 5.37B | 2.34B | 77.39% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Fresenius Medical Care AG | 21.46B |
| Tenet Healthcare | 20.97B |
| Universal Health Services | 15.42B |
| DaVita | 12.67B |
| Incyte | 4.08B |
| Dr. Reddy's Laboratories | 3.58B |
| BioMarin Pharmaceutical | 2.75B |
| Revvity | 2.72B |
GMAB News
- 17 days ago - Genmab to Hold 2024 R&D Update and ASH Data Review Meeting - GlobeNewsWire
- 19 days ago - Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL) - Business Wire
- 20 days ago - Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) in Preliminary Analysis - Business Wire
- 20 days ago - Genmab Is Too Attractive To Ignore - Seeking Alpha
- 20 days ago - Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) - Business Wire
- 25 days ago - Capital Increase in Genmab as a Result of Employee Warrant Exercise - GlobeNewsWire
- 25 days ago - Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons - GlobeNewsWire
- 4 weeks ago - Genmab to Present at Citi's Global Healthcare Conference - GlobeNewsWire